368 related articles for article (PubMed ID: 36473631)
1. The addition of camrelizumab is effective and safe among unresectable hepatocellular carcinoma patients who progress after drug-eluting bead transarterial chemoembolization plus apatinib therapy.
Wang M; Sun L; Han X; Ren J; Li H; Wang W; Xu W; Liang C; Duan X
Clin Res Hepatol Gastroenterol; 2023 Jan; 47(1):102060. PubMed ID: 36473631
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of drug-eluting bead transarterial chemoembolization (DEB-TACE) plus apatinib versus DEB-TACE alone in treating huge hepatocellular carcinoma patients.
Li N; Chen J
Ir J Med Sci; 2022 Dec; 191(6):2611-2617. PubMed ID: 35083645
[TBL] [Abstract][Full Text] [Related]
3. Late combination of transarterial chemoembolization with apatinib and camrelizumab for unresectable hepatocellular carcinoma is superior to early combination.
Ju S; Zhou C; Hu J; Wang Y; Wang C; Liu J; Yang C; Huang S; Li T; Chen Y; Bai Y; Yao W; Xiong B
BMC Cancer; 2022 Mar; 22(1):335. PubMed ID: 35346114
[TBL] [Abstract][Full Text] [Related]
4. Transcatheter arterial chemoembolization plus apatinib with or without camrelizumab for unresectable hepatocellular carcinoma: a multicenter retrospective cohort study.
Duan X; Li H; Kuang D; Chen P; Zhang K; Li Y; He X; Xing C; Wang H; Liu Y; Xie L; Zhang S; Zhang Q; Zhu P; Dong H; Xie J; Li H; Wang Y; Shi M; Jiang G; Xu Y; Zhou S; Shang C; Ren J; Han X
Hepatol Int; 2023 Aug; 17(4):915-926. PubMed ID: 37012542
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Drug-Eluting Beads Transarterial Chemoembolization Plus Camrelizumab Compared With Conventional Transarterial Chemoembolization Plus Camrelizumab for Unresectable Hepatocellular Carcinoma.
Ren Y; Guo Y; Chen L; Sun T; Zhang W; Sun B; Zhu L; Xiong F; Zheng C
Cancer Control; 2022; 29():10732748221076806. PubMed ID: 35343254
[TBL] [Abstract][Full Text] [Related]
6. Real-world efficacy and safety of TACE plus camrelizumab and apatinib in patients with HCC (CHANCE2211): a propensity score matching study.
Jin ZC; Zhong BY; Chen JJ; Zhu HD; Sun JH; Yin GW; Ge NJ; Luo B; Ding WB; Li WH; Chen L; Wang YQ; Zhu XL; Yang WZ; Li HL; Teng GJ;
Eur Radiol; 2023 Dec; 33(12):8669-8681. PubMed ID: 37368105
[TBL] [Abstract][Full Text] [Related]
7. Drug-eluting bead transarterial chemoembolization followed by apatinib is effective and safe in treating hepatocellular carcinoma patients with BCLC stage C.
Ju S; Wang W; Chen P; Li F; Li H; Wang M; Han X; Ren J; Duan X
Clin Res Hepatol Gastroenterol; 2022 Mar; 46(3):101859. PubMed ID: 34999249
[TBL] [Abstract][Full Text] [Related]
8. A retrospective pilot study of transarterial chemoembolisation using camrelizumab-eluting Callisphere beads for unresectable hepatocellular carcinoma.
Shi X; Wang Y; Ren J; Han X; Bi Y
BMC Cancer; 2023 Nov; 23(1):1144. PubMed ID: 38001447
[TBL] [Abstract][Full Text] [Related]
9. Apatinib plus drug-eluting bead transarterial chemoembolization as bridging therapy to surgical resection displays an acceptable efficacy and safety profile in hepatocellular carcinoma patients.
Yan J; Sun Y; Fan D; Mu W
Indian J Cancer; 2023 Oct; 60(4):562-569. PubMed ID: 36861729
[TBL] [Abstract][Full Text] [Related]
10. Drug-eluting bead transarterial chemoembolization (TACE) exhibits superior efficacy and equal tolerance to conventional TACE in hepatocellular carcinoma patients with conventional TACE history.
Tang J; Huang Z; Xu J; Lv Q; Wang P
Clin Res Hepatol Gastroenterol; 2022 Mar; 46(3):101814. PubMed ID: 34597848
[TBL] [Abstract][Full Text] [Related]
11. The second-line treatment of hepatocellular carcinoma with CalliSpheres drug-eluting bead transarterial chemoembolization combined with regorafenib: A safety and efficacy analysis.
Liu S; Liu C; Wang Q; Liu Y; Wang D; Zhao G; Yu G
Ir J Med Sci; 2024 Jun; 193(3):1215-1222. PubMed ID: 38300460
[TBL] [Abstract][Full Text] [Related]
12. Apatinib Plus Camrelizumab With/Without Chemoembolization for Hepatocellular Carcinoma: A Real-World Experience of a Single Center.
Ju S; Zhou C; Yang C; Wang C; Liu J; Wang Y; Huang S; Li T; Chen Y; Bai Y; Yao W; Xiong B
Front Oncol; 2021; 11():835889. PubMed ID: 35174073
[TBL] [Abstract][Full Text] [Related]
13. Transarterial chemoembolization (TACE) plus apatinib vs. TACE alone for hepatocellular carcinoma.
Li N; Yang P; Fang J
Clin Res Hepatol Gastroenterol; 2022 Nov; 46(9):102022. PubMed ID: 36089248
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Treatment Response and Survival Profiles Between Drug-Eluting Bead Transarterial Chemoembolization and Conventional Transarterial Chemoembolization in Chinese Hepatocellular Carcinoma Patients: A Prospective Cohort Study.
Wen P; Chen SD; Wang JR; Zeng YH
Oncol Res; 2019 May; 27(5):583-592. PubMed ID: 31053181
[TBL] [Abstract][Full Text] [Related]
15. Transarterial chemoembolization (TACE) plus apatinib-combined therapy versus TACE alone in the treatment of intermediate to advanced hepatocellular carcinoma patients: A real-world study.
Wang H; Liu D; Wang C; Yu S; Jin G; Wang C; Zhang B; Zhang D; Shao D
Clin Res Hepatol Gastroenterol; 2022; 46(6):101869. PubMed ID: 35108656
[TBL] [Abstract][Full Text] [Related]
16. Drug-eluting bead transarterial chemoembolization is an effective downstaging option for subsequent radical treatments in patients with hepatocellular carcinoma: A cohort study.
Cai L; Li H; Guo J; Zhao W; Duan Y; Hou X; Cheng L; Du H; Shao X; Diao Z; Li C
Clin Res Hepatol Gastroenterol; 2021 Jul; 45(4):101535. PubMed ID: 33121882
[TBL] [Abstract][Full Text] [Related]
17. Transarterial chemoembolization plus apatinib with or without camrelizumab for unresected hepatocellular carcinoma: A two-center propensity score matching study.
Zhu D; Ma K; Yang W; Zhou HF; Shi Q; Ren JW; Xie YG; Liu S; Shi HB; Zhou WZ
Front Oncol; 2022; 12():1057560. PubMed ID: 36439471
[TBL] [Abstract][Full Text] [Related]
18. Comparing the effectiveness and safety of Sorafenib plus TACE with Apatinib plus TACE for treating patients with unresectable hepatocellular carcinoma: a multicentre propensity score matching study.
Yin L; Liu KC; Lv WF; Lu D; Tan YL; Wang GX; Dai JY; Zhu XH; Jiang B
Cancer Imaging; 2023 May; 23(1):52. PubMed ID: 37254146
[TBL] [Abstract][Full Text] [Related]
19. Drug-Eluting Bead Transarterial Chemoembolization Versus Radiofrequency Ablation as an Initial Treatment of Single Small (≤ 3 cm) Hepatocellular Carcinoma.
Lee S; Jeong YY; Lee BC; Shin SS; Heo SH; Kim HO; Park C; Jeong WG
J Korean Med Sci; 2023 Oct; 38(42):e362. PubMed ID: 37904659
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of the Combination of Transarterial Chemoembolization with Camrelizumab plus Apatinib for Advanced Hepatocellular Carcinoma: A Retrospective Study of 38 Patients from a Single Center.
Zhang JX; Chen YX; Zhou CG; Liu J; Liu S; Shi HB; Zu QQ
Can J Gastroenterol Hepatol; 2022; 2022():7982118. PubMed ID: 35586608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
